INmune Bio (NASDAQ: INMB), a clinical-stage immunology
company focused on developing treatments that harness the patient’s innate
immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder
and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will
be presenting at the first ever Targeting Innate Immunity Congress. Dr. Tesi and Dr.
Lowdell will also be instructing a course on the role of the tumor
microenvironment (“TME”) in immunosuppression at the event, which will take
place September 23rd – 25th in Cambridge, Massachusetts. INmune is set to use
this opportunity to showcase its two leading innate compounds to industry
leaders, experts, academic researchers and clinicians in the field of innate
immunity. In addition, Dr. Tesi will also take part in a speaking engagement in
Philadelphia at the second annual MarketsandMarkets Next Gen Immuno-Oncology Congress on
September 19th.
To view the full press release, visit http://ibn.fm/dSeP8
About INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage biotechnology company
developing therapies targeting the innate immune system to fight disease.
INmune Bio is developing three product platforms: two products that reengineer
the patient’s innate immune system’s response to cancer and one product to
treat neuroinflammation that is currently focused on Alzheimer’s disease.
INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s
NK cells to attack minimal residual disease, the remaining cancer cells that
are difficult to detect, which often cause relapse. INB03 inhibits
myeloid-derived suppressor cells (“MDSC”), which often cause resistance to
immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets
neuroinflammation, which causes microglial activation and neuronal cell death.
INmune Bio’s product platforms utilize a precision medicine approach for the
treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. For more information, visit the company’s website
at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment